浙江交科(002061.SZ):下屬公司聯合籤屬甬舟高速複線PPP項目投資協議
格隆匯5月13日丨浙江交科(002061.SZ)公佈,近日,浙江交工、交工路建及聯合體各方與舟山市大橋建設管理中心簽署了《甬舟高速公路複線金塘至大沙段工程PPP項目投資協議》。根據投資協議,社會資本方與舟山交通投資集團有限公司(簡稱“舟山交投集團”)成立項目公司,項目公司的註冊資本為6億元,浙江交工佔項目公司股權的0.45%,出資金額270萬元;交工路建佔項目公司股權的0.03%,出資金額18萬元。
該項目總投資為107.54億元,項目資本金為37.64億元人民幣,其中,浙江交工出資1695萬元,交工路建出資113萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.